-
1
-
-
0028819660
-
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
-
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311–8.
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1311-1318
-
-
Goldstein, NI1
Prewett, M2
Zuklys, K3
Rockwell, P4
Mendelsohn, J.5
-
2
-
-
10744221013
-
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
-
Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984–90.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 984-990
-
-
Foon, KA1
Yang, XD2
Weiner, LM3
Belldegrun, AS4
Figlin, RA5
Crawford, J6
-
3
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, CS1
Khambata-Ford, S2
Jonker, DJ3
O'Callaghan, CJ4
Tu, D5
Tebbutt, NC6
-
4
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011–9.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E1
Kohne, CH2
Lang, I3
Folprecht, G4
Nowacki, MP5
Cascinu, S6
-
5
-
-
84898666033
-
Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
-
abstract nr LBA17
-
Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur Cancer Congr (ECCO-ESMO-ESTRO) 2013; abstract nr LBA17.
-
(2013)
Eur Cancer Congr (ECCO-ESMO-ESTRO)
-
-
Stintzing, S1
Jung, A2
Rossius, L3
Modest, DP4
Fischer von Weikersthal, L5
Decker, T6
-
6
-
-
84859403854
-
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer
-
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer. JAMA 2012;307:1383–93.
-
(2012)
JAMA
, vol.307
, pp. 1383-1393
-
-
Alberts, SR1
Sargent, DJ2
Nair, S3
Mahoney, MR4
Mooney, M5
Thibodeau, SN6
-
7
-
-
84903547973
-
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
-
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:862–73.
-
(2014)
Lancet Oncol
, vol.15
, pp. 862-873
-
-
Taieb, J1
Tabernero, J2
Mini, E3
Subtil, F4
Folprecht, G5
Van Laethem, JL6
-
8
-
-
84898863809
-
RAS Mutations and Cetuximab in Locally Advanced Rectal Cancer: Results of the EXPERT-C Trial
-
Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, et al. RAS Mutations and Cetuximab in Locally Advanced Rectal Cancer: Results of the EXPERT-C Trial. Eur J Cancer 2014; 50:1430–6.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1430-1436
-
-
Sclafani, F1
Gonzalez, D2
Cunningham, D3
Hulkki Wilson, S4
Peckitt, C5
Giralt, J6
-
9
-
-
84905283114
-
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial
-
Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst 2014;106(7).
-
(2014)
J Natl Cancer Inst
, vol.106
, Issue.7
-
-
Sclafani, F1
Gonzalez, D2
Cunningham, D3
Hulkki Wilson, S4
Peckitt, C5
Tabernero, J6
-
10
-
-
77951614830
-
Monoclonal antibodies: versatile platforms for cancer immunotherapy
-
Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317–27.
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 317-327
-
-
Weiner, LM1
Surana, R2
Wang, S.3
-
11
-
-
84871770952
-
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
-
Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013;6:1.
-
(2013)
J Hematol Oncol
, vol.6
, pp. 1
-
-
Mellor, JD1
Brown, MP2
Irving, HR3
Zalcberg, JR4
Dobrovic, A.5
-
12
-
-
0025808211
-
A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding
-
Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147: 1338–43.
-
(1991)
J Immunol
, vol.147
, pp. 1338-1343
-
-
Warmerdam, PA1
van de Winkel, JG2
Vlug, A3
Westerdaal, NA4
Capel, PJ.5
-
13
-
-
0024414878
-
Molecular basis for a polymorphism involving Fc receptor II on human monocytes
-
Clark MR, Clarkson SB, Ory PA, Stollman N, Goldstein IM. Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J Immunol 1989;143:1731–4.
-
(1989)
J Immunol
, vol.143
, pp. 1731-1734
-
-
Clark, MR1
Clarkson, SB2
Ory, PA3
Stollman, N4
Goldstein, IM.5
-
14
-
-
0034076307
-
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
-
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6: 443–6.
-
(2000)
Nat Med
, vol.6
, pp. 443-446
-
-
Clynes, RA1
Towers, TL2
Presta, LG3
Ravetch, JV.4
-
15
-
-
3042743884
-
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship
-
Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664–9.
-
(2004)
Cancer Res
, vol.64
, pp. 4664-4669
-
-
Dall'Ozzo, S1
Tartas, S2
Paintaud, G3
Cartron, G4
Colombat, P5
Bardos, P6
-
16
-
-
42949157368
-
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer
-
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer. J Clin Oncol 2008;26:1789–96.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1789-1796
-
-
Musolino, A1
Naldi, N2
Bortesi, B3
Pezzuolo, D4
Capelletti, M5
Missale, G6
-
17
-
-
65549139376
-
FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
-
Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009;58:997–1006.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 997-1006
-
-
Taylor, RJ1
Chan, SL2
Wood, A3
Voskens, CJ4
Wolf, JS5
Lin, W6
-
18
-
-
84863743780
-
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)
-
Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30:1620–7.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1620-1627
-
-
Dewdney, A1
Cunningham, D2
Tabernero, J3
Capdevila, J4
Glimelius, B5
Cervantes, A6
-
19
-
-
61449239114
-
Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
-
Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122–9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1122-1129
-
-
Bibeau, F1
Lopez-Crapez, E2
Di Fiore, F3
Thezenas, S4
Ychou, M5
Blanchard, F6
-
20
-
-
34548509226
-
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
-
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712–8.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3712-3718
-
-
Zhang, W1
Gordon, M2
Schultheis, AM3
Yang, DY4
Nagashima, F5
Azuma, M6
-
21
-
-
78650245376
-
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study)
-
Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010;30:4209–17.
-
(2010)
Anticancer Res
, vol.30
, pp. 4209-4217
-
-
Zhang, W1
Azuma, M2
Lurje, G3
Gordon, MA4
Yang, D5
Pohl, A6
-
22
-
-
82055175693
-
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
-
Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011;11: 496.
-
(2011)
BMC Cancer
, vol.11
, pp. 496
-
-
Dahan, L1
Norguet, E2
Etienne-Grimaldi, MC3
Formento, JL4
Gasmi, M5
Nanni, I6
-
23
-
-
77955950937
-
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
-
Paez D, Pare L, Espinosa I, Salazar J, del Rio E, Barnadas A, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci 2010;101:2048–53.
-
(2010)
Cancer Sci
, vol.101
, pp. 2048-2053
-
-
Paez, D1
Pare, L2
Espinosa, I3
Salazar, J4
del Rio, E5
Barnadas, A6
-
24
-
-
84864131126
-
Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
-
Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ, et al. Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 2012;48:1774–80.
-
(2012)
Eur J Cancer
, vol.48
, pp. 1774-1780
-
-
Rodriguez, J1
Zarate, R2
Bandres, E3
Boni, V4
Hernandez, A5
Sola, JJ6
-
25
-
-
84859375010
-
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab- irinotecan
-
Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, et al. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab- irinotecan. Br J Clin Pharmacol 2012; 73:776–85.
-
(2012)
Br J Clin Pharmacol
, vol.73
, pp. 776-785
-
-
Etienne-Grimaldi, MC1
Bennouna, J2
Formento, JL3
Douillard, JY4
Francoual, M5
Hennebelle, I6
-
26
-
-
84896689696
-
KRAS mutation confers resistance to antibody dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells
-
Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, et al. KRAS mutation confers resistance to antibody dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 2014;134:2146–55.
-
(2014)
Int J Cancer
, vol.134
, pp. 2146-2155
-
-
Nakadate, Y1
Kodera, Y2
Kitamura, Y3
Shirasawa, S4
Tachibana, T5
Tamura, T6
-
27
-
-
84862822870
-
Genetic polymorphisms of FcgRIIa and FcgRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer
-
Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP, et al. Genetic polymorphisms of FcgRIIa and FcgRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. Oncology 2012;82:83–9.
-
(2012)
Oncology
, vol.82
, pp. 83-89
-
-
Park, SJ1
Hong, YS2
Lee, JL3
Ryu, MH4
Chang, HM5
Kim, KP6
-
28
-
-
77953276067
-
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
-
Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010;46:1829–34.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1829-1834
-
-
Pander, J1
Gelderblom, H2
Antonini, NF3
Tol, J4
van Krieken, JH5
van der Straaten, T6
-
29
-
-
84869221346
-
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
-
Calemma R, Ottaiano A, Trotta AM, Nasti G, Romano C, Napolitano M, et al. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med 2012;10:232.
-
(2012)
J Transl Med
, vol.10
, pp. 232
-
-
Calemma, R1
Ottaiano, A2
Trotta, AM3
Nasti, G4
Romano, C5
Napolitano, M6
-
30
-
-
84893651406
-
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
-
Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J 2014;14:14–9.
-
(2014)
Pharmacogenomics J
, vol.14
, pp. 14-19
-
-
Negri, FV1
Musolino, A2
Naldi, N3
Bortesi, B4
Missale, G5
Laccabue, D6
-
31
-
-
84862807556
-
An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy
-
(suppl; abstr 3528)
-
Geva R, Jensen BV, Fountzilas G, Yoshino T, Paez D, Montagut C, et al. An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. J Clin Oncol 29: 2011 (suppl; abstr 3528).
-
(2011)
J Clin Oncol
, vol.29
-
-
Geva, R1
Jensen, BV2
Fountzilas, G3
Yoshino, T4
Paez, D5
Montagut, C6
-
32
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
-
De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594–603.
-
(2011)
Lancet Oncol
, vol.12
, pp. 594-603
-
-
De Roock, W1
De Vriendt, V2
Normanno, N3
Ciardiello, F4
Tejpar, S.5
-
33
-
-
34447298092
-
Trastuzumab causes antibody-dependent cellular cytotoxicity- mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
-
Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity- mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007; 6:2065–72.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2065-2072
-
-
Barok, M1
Isola, J2
Palyi-Krekk, Z3
Nagy, P4
Juhasz, I5
Vereb, G6
-
34
-
-
0032695575
-
The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells
-
Abdullah N, Greenman J, Pimenidou A, Topping KP, Monson JR. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol Immunother 1999;48:517–24.
-
(1999)
Cancer Immunol Immunother
, vol.48
, pp. 517-524
-
-
Abdullah, N1
Greenman, J2
Pimenidou, A3
Topping, KP4
Monson, JR.5
-
35
-
-
0037108686
-
Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer
-
Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002;62: 5813–7.
-
(2002)
Cancer Res
, vol.62
, pp. 5813-5817
-
-
Kono, K1
Takahashi, A2
Ichihara, F3
Sugai, H4
Fujii, H5
Matsumoto, Y.6
-
36
-
-
54249155585
-
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor
-
Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res 2008;68:8004–13.
-
(2008)
Cancer Res
, vol.68
, pp. 8004-8013
-
-
Hu, YP1
Patil, SB2
Panasiewicz, M3
Li, W4
Hauser, J5
Humphrey, LE6
-
37
-
-
77956996167
-
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
-
Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010;127:1941–7.
-
(2010)
Int J Cancer
, vol.127
, pp. 1941-1947
-
-
Scartozzi, M1
Mandolesi, A2
Giampieri, R3
Pierantoni, C4
Loupakis, F5
Zaniboni, A6
-
38
-
-
84865787643
-
Cancers of the colon and rectum: identical or fraternal twins?
-
Hong TS, Clark JW, Haigis KM. Cancers of the colon and rectum: identical or fraternal twins? Cancer Discov 2012;2:117–21.
-
(2012)
Cancer Discov
, vol.2
, pp. 117-121
-
-
Hong, TS1
Clark, JW2
Haigis, KM.3
-
39
-
-
0030611643
-
FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, independently of the FcgRIIIa-48L/R/H phenotype
-
Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, independently of the FcgRIIIa-48L/R/H phenotype. Blood 1997;90:1109–14.
-
(1997)
Blood
, vol.90
, pp. 1109-1114
-
-
Koene, HR1
Kleijer, M2
Algra, J3
Roos, D4
von dem Borne, AE5
de Haas, M.6
-
40
-
-
0642373290
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
-
Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940–7.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3940-3947
-
-
Weng, WK1
Levy, R.2
-
41
-
-
77952585049
-
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhances their susceptibility to EGFR- targeted antibody-dependent cell-mediated cytotoxicity
-
Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhances their susceptibility to EGFR- targeted antibody-dependent cell-mediated cytotoxicity. Eur J Cancer 2010;46:1703–11.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1703-1711
-
-
Correale, P1
Marra, M2
Remondo, C3
Migali, C4
Misso, G5
Arcuri, FP6
-
42
-
-
70350647412
-
Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
-
De Souza AP, Bonorino C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 2009;9:1317–32.
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 1317-1332
-
-
De Souza, AP1
Bonorino, C.2
-
43
-
-
39449096960
-
Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype
-
Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. Cancer Res 2008; 68:976–80.
-
(2008)
Cancer Res
, vol.68
, pp. 976-980
-
-
Congy-Jolivet, N1
Bolzec, A2
Ternant, D3
Ohresser, M4
Watier, H5
Thibault, G.6
|